New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Investor Update - February 25, 2024 Category: Pharmaceuticals Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Media News - February 25, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Investor Update - February 16, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Media News - February 16, 2024 Category: Pharmaceuticals Source Type: news
How Does Rituximab for Pemphigus Fare in the Long Term? How Does Rituximab for Pemphigus Fare in the Long Term?
This marks the first long-term follow-up data from patients in the Ritux 3 trial who received rituximab as a first-line agent.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - January 24, 2024 Category: Dermatology Tags: Dermatology Source Type: news
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction17 million people in the U.S. have confirmed food allergies and more than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2,3Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration ...
Source: Roche Media News - December 19, 2023 Category: Pharmaceuticals Source Type: news
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction17 million people in the U.S. have confirmed food allergies and more than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2,3Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration ...
Source: Roche Investor Update - December 19, 2023 Category: Pharmaceuticals Source Type: news
Pemphigus Vulgaris After the Second Dose of COVID-19 Vaccine Pemphigus Vulgaris After the Second Dose of COVID-19 Vaccine
This report details a case of new-onset pemphigus vulgaris, a potentially severe autoimmune blistering disease, after a series of COVID-19 vaccinations.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2023 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Cell-killing cancer therapy shows promise for a devastating autoimmune disorder
Opening a new frontier in fighting autoimmune disease, researchers have successfully treated five lupus patients with a novel cell therapy that turns run-of-the-mill immune cells into specialized hunters of rogue cells helping fuel illness. The patients treated with the new therapy all saw their severe symptoms, including kidney and other organ dysfunction, largely disappear.
The results “are phenomenal,” says Betty Diamond, an immunologist and rheumatologist at the Feinstein Institutes for Medical Research who cares for lupus patients and was not involved in the work. Despite her excitement, she cautions that th...
Source: ScienceNOW - September 15, 2022 Category: Science Source Type: news
For Pemphigus, Rituximab Is First Line, Expert Says For Pemphigus, Rituximab Is First Line, Expert Says
Lower healthcare costs and efficacy put rituximab ahead of traditional treatments, such as corticosteroids, doxycycline, and immunomodulators, for the autoimmune blistering disease, an expert said.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 1, 2022 Category: Dermatology Tags: Dermatology News Source Type: news
Woman who dropped to four stone with rare autoimmune disease says OnlyFans money 'saved my life'
Ex legal worker Rachael Huckle, from Wrexham, says money made from racy cosplay photos have paid for private treatment for pemphigus, which causes blisters in the digestive system. (Source: the Mail online | Health)
Source: the Mail online | Health - September 24, 2021 Category: Consumer Health News Source Type: news
What Triggers Pemphigus Vulgaris?
Title: What Triggers Pemphigus Vulgaris?Category: Diseases and ConditionsCreated: 8/24/2021 12:00:00 AMLast Editorial Review: 8/24/2021 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - August 24, 2021 Category: Dermatology Source Type: news
Rituximab Superior to Mycophenolate Mofetil in Pemphigus Vulgaris Study Rituximab Superior to Mycophenolate Mofetil in Pemphigus Vulgaris Study
Significantly more patients on rituximab achieved a complete sustained remission in the interim analysis of the trial, which enrolled 135 patients with moderate to severe pemphigus.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 12, 2021 Category: Dermatology Tags: Dermatology News Source Type: news
Rituximab, Mycophenolate Mofetil Compared for Pemphigus Vulgaris
WEDNESDAY, May 19, 2021 -- For patients with pemphigus vulgaris, rituximab is superior to mycophenolate mofetil for producing sustained complete remission at 52 weeks, according to a study published online May 19 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 19, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
● Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news
